[go: up one dir, main page]

DK1995242T3 - Hidtil ukendt 1,2,3,4-tetrahydroquinoxalinderivat med glucocorticoidreceptorbindingsaktivitet. - Google Patents

Hidtil ukendt 1,2,3,4-tetrahydroquinoxalinderivat med glucocorticoidreceptorbindingsaktivitet.

Info

Publication number
DK1995242T3
DK1995242T3 DK07738592.0T DK07738592T DK1995242T3 DK 1995242 T3 DK1995242 T3 DK 1995242T3 DK 07738592 T DK07738592 T DK 07738592T DK 1995242 T3 DK1995242 T3 DK 1995242T3
Authority
DK
Denmark
Prior art keywords
binding activity
receptor binding
glucocorticoid receptor
newly known
tetrahydroquinoxaline derivative
Prior art date
Application number
DK07738592.0T
Other languages
English (en)
Inventor
Masato Nagatsuka
Sachiko Kobayashi
Mamoru Matsuda
Toshiyuki Mori
Kenji Kawashima
Minoru Yamamoto
Masatomo Kato
Miwa Takai
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DK1995242T3 publication Critical patent/DK1995242T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/46—Phenazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK07738592.0T 2006-03-14 2007-03-14 Hidtil ukendt 1,2,3,4-tetrahydroquinoxalinderivat med glucocorticoidreceptorbindingsaktivitet. DK1995242T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2006069739 2006-03-14
JP2006255039 2006-08-22
PCT/JP2007/055122 WO2007105766A1 (ja) 2006-03-14 2007-03-14 グルココルチコイド受容体結合活性を有する新規１，２，３，４－テトラヒドロキノキサリン誘導体

Publications (1)

Publication Number Publication Date
DK1995242T3 true DK1995242T3 (da) 2012-12-17

Family

ID=38509582

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07738592.0T DK1995242T3 (da) 2006-03-14 2007-03-14 Hidtil ukendt 1,2,3,4-tetrahydroquinoxalinderivat med glucocorticoidreceptorbindingsaktivitet.

Country Status (16)

Country Link
US (2) US8551991B2 (da)
EP (1) EP1995242B1 (da)
KR (2) KR101426966B1 (da)
CN (1) CN101400659B (da)
AU (1) AU2007225693A1 (da)
BR (1) BRPI0708767A2 (da)
CA (1) CA2643070C (da)
DK (1) DK1995242T3 (da)
ES (1) ES2396711T3 (da)
MX (1) MX2008011779A (da)
NO (1) NO20084262L (da)
PL (1) PL1995242T3 (da)
PT (1) PT1995242E (da)
RU (1) RU2008140525A (da)
SI (1) SI1995242T1 (da)
WO (1) WO2007105766A1 (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2396711T3 (es) 2006-03-14 2013-02-25 Santen Pharmaceutical Co., Ltd Nuevo derivado de 1,2,3,4-tetrahidroquinoxalina que tiene actividad de unión al receptor de glucocorticoides
WO2008146871A1 (ja) * 2007-05-29 2008-12-04 Santen Pharmaceutical Co., Ltd. グルココルチコイド受容体結合活性を有する、スルホン酸エステル又はスルホン酸アミド構造を導入したフェニル基を置換基として有する新規１，２，３，４－テトラヒドロキノキサリン誘導体
WO2009035068A1 (ja) * 2007-09-13 2009-03-19 Santen Pharmaceutical Co., Ltd. 新規１，３，３－トリメチル－７－フェニル－３，４－ジヒドロ－１ｈ－キノキサリン－２－オン誘導体
WO2009035067A1 (ja) * 2007-09-13 2009-03-19 Santen Pharmaceutical Co., Ltd. １，３，３－トリメチル－７－フェニル－３，４－ジヒドロ－１ｈ－キノキサリン－２－オン誘導体からなるグルココルチコイド受容体アゴニスト
MX2011002677A (es) * 2008-09-12 2011-04-12 Santen Pharma Co Ltd Agonista del receptor de glucocorticoide que comprende nuevos derivados de 1,2,3,-4-tetrahidroquinoxalina que contienen un grupo fenilo que tiene una estructura de ester de acido sulfonico introducida en el mismo como sustituyente.
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
HK1220462A1 (zh) 2013-08-09 2017-05-05 参天制药株式会社 3，3－二甲基－3，4－二氢－1h－喹喔啉－2－酮衍生物的制造方法及该制造方法的中间体
US10047075B2 (en) 2014-01-24 2018-08-14 Purdue Pharma L.P. Pyridines and pyrimidines and use thereof
CN104628661A (zh) * 2015-02-05 2015-05-20 北京理工大学 一类喹喔啉酮衍生物作为醛糖还原酶抑制剂的结构、制备方法及用途
CN105037425B (zh) * 2015-07-28 2017-06-20 华侨大学 一种喹喔啉‑2(1h)‑酮c‑3位膦酸化合物的合成方法
EP3342768A4 (en) 2015-08-25 2019-01-23 Santen Pharmaceutical Co., Ltd. [4- (1,3,3-TRIMETHYL-2-OXO-3,4-DIHYDRO-1H-CHINOXALIN-7-YL) PHENOXY] ETHYLOXY COMPOUND OR SALT THEREOF
CA3067332A1 (en) 2017-06-16 2018-12-20 The Doshisha Mtor-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof
WO2018230713A1 (ja) 2017-06-16 2018-12-20 学校法人同志社 カスパーゼ阻害活性を有する化合物、これらの化合物を含む、角膜内皮の症状、障害または疾患を治療または予防するための医薬およびその応用
US11093563B2 (en) * 2018-02-05 2021-08-17 Microsoft Technology Licensing, Llc Sharing measured values of physical space parameters
PT3823971T (pt) 2018-07-20 2022-10-26 Gruenenthal Gmbh Derivados substituídos de triazolo quinoxalina
TWI811400B (zh) * 2018-07-20 2023-08-11 德商歌林達有限公司 經進一步取代之三唑并喹噁啉衍生物
CN109574811B (zh) * 2018-11-22 2021-12-24 中山大学 一种阿尼芬净侧链中间体对戊氧基三联苯甲酸的制备方法
CN111138398A (zh) * 2019-12-31 2020-05-12 陕西国际商贸学院 一种2-(2-氨基-3-甲氧苯基)色酮的合成工艺
EP4090661B1 (en) * 2020-01-17 2025-03-12 Grünenthal GmbH Quinoxaline derivatives as modulators of the glucocorticoid receptor
ES2976780T3 (es) * 2020-01-17 2024-08-08 Gruenenthal Gmbh Derivados de quinoxalina
CN115819356B (zh) * 2022-03-16 2025-05-06 中国中医科学院中药研究所 一种制备四氢喹喔啉类化合物的方法
CN115160348B (zh) * 2022-07-06 2024-06-21 中山大学 一种光照下无金属催化的芳香c-h键直接硼化反应的方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT509398E (pt) 1991-04-15 2002-02-28 Aventis Pharma Gmbh Quinoxalinas processo para a sua preparacao e sua utilizacao
US6369057B1 (en) 1991-04-15 2002-04-09 Aventis Pharma Deutschland Gmbh Quinoxalines, processes for their preparation and their use
WO1997020578A1 (en) * 1995-12-04 1997-06-12 University Of Miami Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance
US6340758B1 (en) * 1997-05-16 2002-01-22 Warner-Lambert Company Conformationally semi-constrained quinoxaline 2,3-diones as neuroprotective agents
EP1201660B1 (en) 2000-10-30 2005-08-31 Pfizer Products Inc. Glucocorticoid receptor modulators
WO2004099192A2 (en) 2003-04-30 2004-11-18 The Institutes Of Pharmaceutical Discovery, Llc Heterocycle substituted carboxylic acids as inhibitors of protein tyrosine phosphatase-1b
US7235662B2 (en) 2003-06-11 2007-06-26 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
AU2005267798A1 (en) * 2004-07-28 2006-02-09 Irm Llc Compounds and compositions as modulators of steroid hormone nuclear receptors
CN102229562B (zh) 2005-09-14 2013-11-13 参天制药株式会社 具有糖皮质激素受体结合活性的1,2-二氢喹啉衍生物
ES2396711T3 (es) * 2006-03-14 2013-02-25 Santen Pharmaceutical Co., Ltd Nuevo derivado de 1,2,3,4-tetrahidroquinoxalina que tiene actividad de unión al receptor de glucocorticoides
JP5054996B2 (ja) 2006-03-14 2012-10-24 参天製薬株式会社 グルココルチコイド受容体結合活性を有する新規１，２，３，４−テトラヒドロキノキサリン誘導体
WO2007112347A1 (en) * 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
CA2668592C (en) 2006-11-14 2016-04-19 Santen Pharmaceutical Co., Ltd. Novel 1,2-dihydroquinoline derivative having substituted phenylchalcogeno lower alkyl group and ester-introduced phenyl group as substituents
WO2008111632A1 (ja) 2007-03-13 2008-09-18 Santen Pharmaceutical Co., Ltd. ２，２，４－トリメチル－６－フェニル－１，２－ジヒドロキノリン誘導体からなるグルココルチコイド受容体アゴニスト
WO2008146871A1 (ja) 2007-05-29 2008-12-04 Santen Pharmaceutical Co., Ltd. グルココルチコイド受容体結合活性を有する、スルホン酸エステル又はスルホン酸アミド構造を導入したフェニル基を置換基として有する新規１，２，３，４－テトラヒドロキノキサリン誘導体
WO2009035068A1 (ja) 2007-09-13 2009-03-19 Santen Pharmaceutical Co., Ltd. 新規１，３，３－トリメチル－７－フェニル－３，４－ジヒドロ－１ｈ－キノキサリン－２－オン誘導体
WO2009035067A1 (ja) 2007-09-13 2009-03-19 Santen Pharmaceutical Co., Ltd. １，３，３－トリメチル－７－フェニル－３，４－ジヒドロ－１ｈ－キノキサリン－２－オン誘導体からなるグルココルチコイド受容体アゴニスト

Also Published As

Publication number Publication date
NO20084262L (no) 2008-10-10
CN101400659A (zh) 2009-04-01
PL1995242T3 (pl) 2013-03-29
US8975256B2 (en) 2015-03-10
SI1995242T1 (sl) 2013-01-31
CN101400659B (zh) 2012-02-29
EP1995242A1 (en) 2008-11-26
US20090111807A1 (en) 2009-04-30
KR20080100281A (ko) 2008-11-14
MX2008011779A (es) 2008-09-25
CA2643070C (en) 2016-01-26
WO2007105766A1 (ja) 2007-09-20
US8551991B2 (en) 2013-10-08
KR101426966B1 (ko) 2014-08-06
CA2643070A1 (en) 2007-09-20
ES2396711T3 (es) 2013-02-25
AU2007225693A1 (en) 2007-09-20
BRPI0708767A2 (pt) 2011-06-14
EP1995242A4 (en) 2010-08-04
PT1995242E (pt) 2012-11-22
RU2008140525A (ru) 2010-04-27
KR20140063907A (ko) 2014-05-27
EP1995242B1 (en) 2012-11-07
US20130303537A1 (en) 2013-11-14

Similar Documents

Publication Publication Date Title
DK1995242T3 (da) Hidtil ukendt 1,2,3,4-tetrahydroquinoxalinderivat med glucocorticoidreceptorbindingsaktivitet.
NL2000583A1 (nl) Pyridine[3,4-b]pyrazinonen.
BRPI0811718A2 (pt) Derivados de 3,3-espiroindolinona
ATE502012T1 (de) 1,1,1-trifluor-2-hydroxy-3-phenylpropan-derivat
ATE469145T1 (de) 4-ä5-methoxy-6-(2-methyl-6-ä1,2,4ütriazol-1-yl-
NL2000537A1 (nl) Aminederivaten.
HRP20151058T1 (xx) Ariloazol-2-il-cijanoetilamino-spojevi, postupak njihove proizvodnje i postupak njihove uporabe
ATE481383T1 (de) 3-aza-bicycloä3.1.0ühexanderivate
NL2000323A1 (nl) Pyrimidine-derivaten.
DK2035398T3 (da) Immobiliseret 1,2-benzisothioazolin-3-on
DK2404994T3 (da) Enzym associeret med equolsyntese.
BRPI0807991A2 (pt) Anticorpos anti-il-23r elaborados.
DK2197900T3 (da) Mutante dobbeltringsluttede receptorpeptider, der inhiberer beta1-adrenoreceptorantistoffer
DE602006020482D1 (de) 1,5-substituierte indol-2-yl amidderivative
DE602007001681D1 (de) 1,3-dioxan-carboxylsäuren
FR2915451B1 (fr) Prolonge avec appui perfectionne.
DK2041093T3 (da) Til behandling af GPR38-receptor medierede sygdomme anvendelige piperazinylderivativer
BRPI0815059A2 (pt) Derivado de 1,3-di-hidroisoindol
NO20053336D0 (no) System for styrt paforing av herbicider.
BRPI0816679A2 (pt) Derivados de ftalazinona.
PL1944290T3 (pl) Nowa pochodna 1-2-dihydrochinoliny mająca aktywność wiązania glukokortykoidowego receptora
EP1992622A4 (en) 4- (3-benzoylaminophenyl) -6,7-dimethoxy-2-METHYLAMINOCHINAZOLINDERIVAT
DK2219662T3 (da) Aktive, opløselige, post-translationelt modificerede neuregulin- isoformer.
IT1393745B1 (it) Sistemazione di supporto dotata di bussola di supporto.
FR2919373B1 (fr) Raccord rapide perfectionne.